Emerging biomarkers, such as DLL3 expression, T-cell-inflamed gene expression profiles, and blood tumor mutational burden, show promise in preliminary studies but require validation in prospective ES-SCLC cohorts (45). This evidence concerns the gene DLL3 and neoplasm.